US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Niagen Bioscience

13.78

-0.6300-4.37%

Volume:394.62K

Turnover:5.50M

Market Cap:1.09B

PE:77.00

High:14.40

Open:14.40

Low:13.63

Close:14.41

Loading ...

Overview Company News Filings

Niagen Bioscience Inc. Conducted Annual Stockholders Meeting

Niagen Bioscience Inc. to Participate at Roth 15th Annual London Conference

Niagen Bioscience Inc. to Participate in Prestigious BIO International Convention in Boston

Niagen Bioscience Is Maintained at Buy by Canaccord Genuity

Niagen Bioscience price target raised to $16 from $13 at Canaccord

U.S. RESEARCH ROUNDUP-Crane, Ryder System, Terex

Niagen Bioscience Inc : Canaccord Genuity Raises Target Price to $16.00 From $13.00

THOMSON REUTERS

BRIEF-Niagen Bioscience Announces First-Ever Peer-Reviewed Study Highlighting Potential Of Nicotinamide Riboside (NR) For Werner Syndrome, A Rare Genetic Disorder

Niagen Bioscience Announces First-Ever Peer-Reviewed Study Highlighting the Potential of Nicotinamide Riboside (Nr) for Werner Syndrome, a Rare Genetic Disorder

THOMSON REUTERS

Niagen Bioscience Is Maintained at Buy by Roth Capital

Roth MKM Sticks to Their Buy Rating for Niagen Bioscience (NAGE)

Niagen Bioscience Inc. to Present at Oppenheimer's 25th Annual Consumer Growth and E-Commerce Conference

Canaccord Genuity Initiates Niagen Bioscience at Buy With $13 Price Target

MT Newswires Live

Niagen Bioscience initiated with a Buy at Canaccord

Niagen Bioscience Inc reports results for the quarter ended March 31 - Earnings Summary

Stock Track | Niagen Bioscience (NAGE) Soars 6.39% After-Hours on Strong Q1 Earnings, Raised Outlook

Stock Track | Niagen Bioscience Soars 6.39% After Hours on Strong Q1 Results and Raised 2025 Outlook

Niagen Bioscience Q1 EPS $0.06 Beats $0.02 Estimate, Sales $30.48M Beat $27.10M Estimate

Niagen Bioscience Inc Outlook 2025 Company Expects Between 20% to 25% Year-Over-Year Revenue Growth

THOMSON REUTERS

Press Release: Niagen Bioscience, Inc. Reports First Quarter 2025 Financial Results and Increases Outlook

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/NAGE/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NAGE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NAGE\",,,,,undefined,":{"symbol":"NAGE","market":"US","secType":"STK","nameCN":"Niagen Bioscience","latestPrice":13.78,"timestamp":1751383302038,"preClose":14.41,"halted":0,"volume":394624,"delay":0,"floatShares":51581706,"shares":78936662,"eps":0.178968,"marketStatus":"Trading","change":-0.63,"latestTime":"07-01 11:21:43 EDT","open":14.4,"high":14.4,"low":13.6302,"amount":5501978.428544,"amplitude":0.053421,"askPrice":13.79,"askSize":27,"bidPrice":13.76,"bidSize":8,"shortable":3,"etf":0,"ttmEps":0.178968,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1751400000000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":14.41,"preHourTrading":{"tag":"盘前","latestPrice":14.4,"preClose":14.41,"latestTime":"09:18 EDT","volume":1565,"amount":22561.886665,"timestamp":1751375924602},"postHourTrading":{"tag":"盘后","latestPrice":14.28,"preClose":14.41,"latestTime":"19:42 EDT","volume":30440,"amount":438362.809,"timestamp":1751326959713},"volumeRatio":1.113854,"impliedVol":0.3013,"impliedVolPercentile":0.0556},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NAGE\",,,,,undefined,":{"symbol":"NAGE","floatShares":51581706,"roa":"12.21%","roe":"33.47%","lyrEps":0.112605,"volumeRatio":1.113854,"shares":78936662,"dividePrice":0,"high":14.4,"amplitude":0.053421,"preClose":14.41,"low":13.6302,"week52Low":2.405,"pbRate":"19.65","psRate":"10.08","week52High":14.69,"institutionHeld":0,"latestPrice":13.78,"committee":-0.542857,"eps":0.178968,"divideRate":0,"volume":394624,"delay":0,"ttmEps":0.178968,"open":14.4,"prevYearClose":5.305,"prevWeekClose":14.22,"prevMonthClose":14.41,"prevQuarterClose":14.41,"fiveDayClose":14.13,"twentyDayClose":11.73,"sixtyDayClose":6.63},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NAGE\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2546729153","title":"Niagen Bioscience Inc. Conducted Annual Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2546729153","media":"Reuters","labels":["executive","conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546729153?lang=en_us&edition=fundamental","pubTime":"2025-06-28 04:04","pubTimestamp":1751054667,"startTime":"0","endTime":"0","summary":"Niagen Bioscience Inc. held its Annual Meeting of Stockholders on June 24, 2025. During the meeting, several proposals were presented and approved. The amendment to the 2017 Equity Incentive Plan, which increases the number of shares available for issuance by 4.75 million shares of common stock, was approved. The Employee Stock Purchase Plan, allowing officers and employees to purchase shares at a discount, was also approved. Additionally, the election of directors was confirmed, with all nominated directors elected to serve.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Niagen Bioscience Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operat","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250627:nNDL3vKCkD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NAGE","BK4121"],"gpt_icon":0},{"id":"2544122704","title":"Niagen Bioscience Inc. to Participate at Roth 15th Annual London Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2544122704","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544122704?lang=en_us&edition=fundamental","pubTime":"2025-06-20 20:32","pubTimestamp":1750422731,"startTime":"0","endTime":"0","summary":"Niagen Bioscience Inc. , a leading authority on NAD+ and healthy aging science, will participate in the Roth 15th Annual London Conference from June 24-26, 2025. The event will take place at the Four Seasons Hotel London at Park Lane, where Niagen Bioscience CFO, Ozan Pamir, will engage in in-person one-on-one meetings with institutional investors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Niagen Bioscience Inc. published the original content used to generate this news brief via Business Wire  on June 20, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250620:nNDLcfq5Kc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NAGE","BK4121"],"gpt_icon":0},{"id":"2542849655","title":"Niagen Bioscience Inc. to Participate in Prestigious BIO International Convention in Boston","url":"https://stock-news.laohu8.com/highlight/detail?id=2542849655","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542849655?lang=en_us&edition=fundamental","pubTime":"2025-06-11 20:31","pubTimestamp":1749645080,"startTime":"0","endTime":"0","summary":"Niagen Bioscience Inc. will participate in the BIO 2025 International Convention, scheduled for June 16-19, 2025, in Boston, Massachusetts. The company, a global authority on NAD+ with a focus on healthy aging, will be seeking to initiate discussions with prospective partners to support the development and monetization of its emerging drug product candidates, focusing on neurodegenerative diseases such as Parkinson's disease and Ataxia Telangiectasia.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Niagen Bioscience Inc. published the original content used to generate this news brief via Business Wire  on June 11, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250611:nNDL8DGDQd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NAGE","BK4121"],"gpt_icon":0},{"id":"2542314918","title":"Niagen Bioscience Is Maintained at Buy by Canaccord Genuity","url":"https://stock-news.laohu8.com/highlight/detail?id=2542314918","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542314918?lang=en_us&edition=fundamental","pubTime":"2025-06-10 20:28","pubTimestamp":1749558480,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NAGE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 10, 2025 08:28 ET (12:28 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NAGE"],"gpt_icon":0},{"id":"2542678315","title":"Niagen Bioscience price target raised to $16 from $13 at Canaccord","url":"https://stock-news.laohu8.com/highlight/detail?id=2542678315","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542678315?lang=en_us&edition=fundamental","pubTime":"2025-06-10 18:35","pubTimestamp":1749551755,"startTime":"0","endTime":"0","summary":"Canaccord raised the firm’s price target on Niagen Bioscience (NAGE) to $16 from $13 and keeps a Buy rating on the shares. Niagen Bioscience announ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/niagen-bioscience-price-target-raised-to-16-from-13-at-canaccord-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/niagen-bioscience-price-target-raised-to-16-from-13-at-canaccord-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NAGE"],"gpt_icon":0},{"id":"2542360076","title":"U.S. RESEARCH ROUNDUP-Crane, Ryder System, Terex","url":"https://stock-news.laohu8.com/highlight/detail?id=2542360076","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542360076?lang=en_us&edition=fundamental","pubTime":"2025-06-10 15:17","pubTimestamp":1749539873,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Crane, Ryder System, TerexJune 10 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Crane, Ryder Sys","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250610:nL4N3SD0GH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1989763005.USD","BK4009","BK4214","R","LU1543694498.USD","LU1923621640.USD","BK4149","ELEV","LU2125910179.SGD","LU2290526834.HKD","BK4539","FERG","BK4161","TEX","INF.UK","LU1861220033.SGD","CR","TTGT","NAGE","LU2360107168.USD","LU2125910336.SGD","BK4232","MUSA","BK4022","BK4139","BK4121","LU1861215975.USD","LU1989773731.SGD","LU1165135440.EUR","BK5058","BK4104","LU1721427968.SGD"],"gpt_icon":0},{"id":"2542153362","title":"Niagen Bioscience Inc : Canaccord Genuity Raises Target Price to $16.00 From $13.00","url":"https://stock-news.laohu8.com/highlight/detail?id=2542153362","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542153362?lang=en_us&edition=fundamental","pubTime":"2025-06-10 14:17","pubTimestamp":1749536261,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250610:nFWN3SD00J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NAGE","BK4121"],"gpt_icon":0},{"id":"2542338090","title":"BRIEF-Niagen Bioscience Announces First-Ever Peer-Reviewed Study Highlighting Potential Of Nicotinamide Riboside (NR) For Werner Syndrome, A Rare Genetic Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2542338090","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542338090?lang=en_us&edition=fundamental","pubTime":"2025-06-09 22:07","pubTimestamp":1749478032,"startTime":"0","endTime":"0","summary":"BRIEF-Niagen Bioscience Announces First-Ever Peer-Reviewed Study Highlighting Potential Of Nicotinamide Riboside (NR) For Werner Syndrome, A Rare Genetic DisorderJune 9 (Reuters) - Niagen Bioscience I","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250609:nTUA7WWG0Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","NAGE"],"gpt_icon":0},{"id":"2542382383","title":"Niagen Bioscience Announces First-Ever Peer-Reviewed Study Highlighting the Potential of Nicotinamide Riboside (Nr) for Werner Syndrome, a Rare Genetic Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2542382383","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542382383?lang=en_us&edition=fundamental","pubTime":"2025-06-09 20:32","pubTimestamp":1749472320,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250609:nTUA7WWG0Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NAGE","BK4121"],"gpt_icon":0},{"id":"2541862067","title":"Niagen Bioscience Is Maintained at Buy by Roth Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2541862067","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541862067?lang=en_us&edition=fundamental","pubTime":"2025-06-07 02:01","pubTimestamp":1749232860,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NAGE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 06, 2025 14:01 ET (18:01 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NAGE"],"gpt_icon":0},{"id":"2541852739","title":"Roth MKM Sticks to Their Buy Rating for Niagen Bioscience (NAGE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2541852739","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541852739?lang=en_us&edition=fundamental","pubTime":"2025-06-06 19:56","pubTimestamp":1749210974,"startTime":"0","endTime":"0","summary":"In a report released today, Sean McGowan from Roth MKM maintained a Buy rating on Niagen Bioscience (NAGE – Research Report), with a price target o...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/roth-mkm-sticks-to-their-buy-rating-for-niagen-bioscience-nage-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/roth-mkm-sticks-to-their-buy-rating-for-niagen-bioscience-nage-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NAGE"],"gpt_icon":0},{"id":"2540441065","title":"Niagen Bioscience Inc. to Present at Oppenheimer's 25th Annual Consumer Growth and E-Commerce Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2540441065","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540441065?lang=en_us&edition=fundamental","pubTime":"2025-06-04 20:32","pubTimestamp":1749040331,"startTime":"0","endTime":"0","summary":"Niagen Bioscience Inc., a leader in NAD+ science with a focus on healthy aging, will participate in Oppenheimer's 25th Annual Consumer Growth and E-Commerce Conference. The event will take place on June 9, where CEO Rob Fried is scheduled for a fireside chat.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Niagen Bioscience Inc. published the original content used to generate this news brief via Business Wire  on June 04, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nNDL5NBsdK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","NAGE"],"gpt_icon":0},{"id":"2538468031","title":"Canaccord Genuity Initiates Niagen Bioscience at Buy With $13 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2538468031","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538468031?lang=en_us&edition=fundamental","pubTime":"2025-05-27 19:08","pubTimestamp":1748344084,"startTime":"0","endTime":"0","summary":"Niagen Bioscience, Inc. (NAGE) has an average rating of buy and mean price target of $11.72, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from m","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NAGE"],"gpt_icon":0},{"id":"2538678454","title":"Niagen Bioscience initiated with a Buy at Canaccord","url":"https://stock-news.laohu8.com/highlight/detail?id=2538678454","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538678454?lang=en_us&edition=fundamental","pubTime":"2025-05-27 17:20","pubTimestamp":1748337611,"startTime":"0","endTime":"0","summary":"Canaccord analyst Susan Anderson initiated coverage of Niagen Bioscience (NAGE) with a Buy rating and $13 price target Published first on TheFly – ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/niagen-bioscience-initiated-with-a-buy-at-canaccord-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/niagen-bioscience-initiated-with-a-buy-at-canaccord-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4121","NAGE"],"gpt_icon":0},{"id":"2533960720","title":"Niagen Bioscience Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2533960720","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533960720?lang=en_us&edition=fundamental","pubTime":"2025-05-08 05:41","pubTimestamp":1746654089,"startTime":"0","endTime":"0","summary":"Niagen Bioscience Inc reports results for the quarter ended March 31 - Earnings SummaryNiagen Bioscience Inc NAGE.OQ reported quarterly adjusted earnings of 6 cents per share for the quarter ended Mar","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250507:nL8N3RF3E1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NAGE"],"gpt_icon":0},{"id":"1132614490","title":"Stock Track | Niagen Bioscience (NAGE) Soars 6.39% After-Hours on Strong Q1 Earnings, Raised Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=1132614490","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132614490?lang=en_us&edition=fundamental","pubTime":"2025-05-08 04:50","pubTimestamp":1746651032,"startTime":"0","endTime":"0","summary":"Shares of Niagen Bioscience  surged 6.39% in after-hours trading following the release of its impressive first-quarter 2025 financial results. The company, which specializes in NAD+ precursor products for healthy aging, reported significant growth across key financial metrics and raised its full-year outlook, sparking investor enthusiasm.Adding to the positive sentiment, Niagen Bioscience raised its full-year 2025 outlook, projecting net sales growth between 20% and 25%, up from its previous est","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["NAGE"],"gpt_icon":0},{"id":"1170170076","title":"Stock Track | Niagen Bioscience Soars 6.39% After Hours on Strong Q1 Results and Raised 2025 Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=1170170076","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1170170076?lang=en_us&edition=fundamental","pubTime":"2025-05-08 04:50","pubTimestamp":1746651031,"startTime":"0","endTime":"0","summary":"Niagen Bioscience  stock surged 6.39% in after-hours trading on Wednesday, following the release of its impressive first-quarter 2025 financial results and an increased full-year outlook. The company, which specializes in NAD+ precursors and healthy aging solutions, reported significant growth across key financial metrics, surpassing analyst expectations.Adding to the positive sentiment, Niagen Bioscience raised its full-year 2025 outlook, projecting net sales growth between 20% and 25%, up from","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Stock Track | Niagen Bioscience Soars 6.39% After Hours on Strong Q1 Results and Raised 2025 Outlook","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["NAGE"],"gpt_icon":0},{"id":"2533696988","title":"Niagen Bioscience Q1 EPS $0.06 Beats $0.02 Estimate, Sales $30.48M Beat $27.10M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2533696988","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533696988?lang=en_us&edition=fundamental","pubTime":"2025-05-08 04:10","pubTimestamp":1746648646,"startTime":"0","endTime":"0","summary":"Niagen Bioscience (NASDAQ:NAGE) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $0.02 by 200 percent. This is a 700 percent increase over losses of $(0.01) per share from the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/05/45266239/niagen-bioscience-q1-eps-0-06-beats-0-02-estimate-sales-30-48m-beat-27-10m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NAGE"],"gpt_icon":0},{"id":"2533496284","title":"Niagen Bioscience Inc Outlook 2025 Company Expects Between 20% to 25% Year-Over-Year Revenue Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2533496284","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533496284?lang=en_us&edition=fundamental","pubTime":"2025-05-08 04:02","pubTimestamp":1746648120,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250507:nTUA287Q80:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4121","NAGE"],"gpt_icon":0},{"id":"2533650509","title":"Press Release: Niagen Bioscience, Inc. Reports First Quarter 2025 Financial Results and Increases Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2533650509","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533650509?lang=en_us&edition=fundamental","pubTime":"2025-05-08 04:02","pubTimestamp":1746648120,"startTime":"0","endTime":"0","summary":"Total net sales of $30.5 million, up $8.3 million or 38% year-over-year, gross margin of 63.4%, net income of $5.1 million and Adjusted EBITDA of $4.9 million for the three months ended March 31, 2025 and increased full year 2025 outlook.Niagen Bioscience, Inc.  today announced financial results for the first quarter of 2025.First Quarter 2025 Financial and Recent Operational Highlights. -- Total net sales were $30.5 million, with $21.5 million from Tru Niagen,up 38%, and 24%, respectively, from the prior year quarter.-- Total Niagen ingredient sales, including food-grade and. -- Sales and marketing expense as a percentage of net sales was 26.6%, an. improvement of 380 basis points, compared to 30.4% from the prior year. improvement of $5.6 million and $0.08 per share from the prior year. -- The Company announced its corporate name change to Niagen Bioscience,in healthy aging through its flagship ingredient, Niagen, reinforcing. its renewed mission: \"There's a better way to age.\". -- O","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","BK4121","NAGE","BK4022","R"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":45,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NAGE\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-07","symbol":"NAGE","fiscalQuarterEnding":"2025/03","expectedEps":0.02,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1746590400000,"reportTimeType":"post","actualEps":0.04},{"market":"US","date":"2025-03-04","symbol":"NAGE","fiscalQuarterEnding":"2024/12","expectedEps":0.02,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1741064400000,"reportTimeType":"post","actualEps":0.03},{"market":"US","date":"2024-10-31","symbol":"NAGE","fiscalQuarterEnding":"2024/09","expectedEps":0.01,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1730347200000,"reportTimeType":"post","actualEps":0.02},{"market":"US","date":"2024-08-07","symbol":"NAGE","fiscalQuarterEnding":"2024/06","expectedEps":-0.03,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723003200000,"reportTimeType":"post","actualEps":0},{"market":"US","date":"2024-05-08","symbol":"NAGE","fiscalQuarterEnding":"2024/03","expectedEps":-0.03,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715140800000,"reportTimeType":"post","actualEps":-0.01}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NAGE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NAGE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4,"buy":0.6,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6,"analysts":5,"updateTime":1748577600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NAGE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NAGE","date":"2025-06-27","current":77.341699,"percent":0.882353,"low":49.393282,"twenty":56.791865,"median":65.523561,"eighty":75.181504,"high":80.324484,"avg":65.429295,"sd":8.662076,"marketCap":1090904668},"quantilePoints":[{"date":"2025-03-21","current":69.624479,"twenty":69.806742,"median":70.080136,"eighty":70.353531,"marketCap":595289295},{"date":"2025-03-28","current":67.346191,"twenty":68.676711,"median":69.624479,"eighty":70.371757,"marketCap":575809933},{"date":"2025-04-04","current":60.420196,"twenty":62.662031,"median":67.938546,"eighty":69.697384,"marketCap":516592673},{"date":"2025-04-11","current":51.67157,"twenty":54.861173,"median":62.880747,"eighty":69.551574,"marketCap":441791924},{"date":"2025-04-17","current":59.600012,"twenty":54.815607,"median":61.696037,"eighty":69.259953,"marketCap":509580103},{"date":"2025-04-25","current":67.255059,"twenty":55.043436,"median":62.151694,"eighty":68.530901,"marketCap":575030758},{"date":"2025-05-02","current":68.895427,"twenty":55.954751,"median":62.880747,"eighty":69.442216,"marketCap":589055899},{"date":"2025-05-09","current":51.710369,"twenty":55.954751,"median":65.022337,"eighty":70.535794,"marketCap":729374756},{"date":"2025-05-16","current":58.761783,"twenty":54.815607,"median":62.789615,"eighty":69.71561,"marketCap":828834951},{"date":"2025-05-23","current":56.859021,"twenty":55.043436,"median":61.650471,"eighty":69.624479,"marketCap":801996485},{"date":"2025-05-30","current":60.552618,"twenty":55.242319,"median":61.364091,"eighty":69.478669,"marketCap":854094682},{"date":"2025-06-06","current":64.414107,"twenty":55.822209,"median":61.604905,"eighty":69.296406,"marketCap":908560979},{"date":"2025-06-13","current":79.132535,"twenty":56.409541,"median":62.698483,"eighty":70.55402,"marketCap":1116164400},{"date":"2025-06-20","current":77.117845,"twenty":56.623974,"median":63.647427,"eighty":71.912091,"marketCap":1087747202},{"date":"2025-06-27","current":77.341699,"twenty":56.791865,"median":65.523561,"eighty":75.181504,"marketCap":1090904668}],"updateTime":1751344990499}}}